Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gottlieb Touts US FDA's Organizational Structure For Advancing Policies During His Tenure

Mar 20 2019

• By Michael Cipriano

Gottlieb at Brookings — • Source: Ferdous Al-Faruque

Related Content

Orphan Drugs Compose Majority Of Novel US Approvals For First Time Ever In 2018

Jan 03 2019

US FDA Reorg: Centers Will Report Directly To Gottlieb; 'Flattened' Structure Will Make Future Political Transitions Easier

Jul 19 2018

Shutdown Bite Tightens At US FDA, But Gene Therapy To Get 50 More Reviewers

Jan 16 2019

New Acting US FDA Commissioner Shares Agency's Clinical Trial Reform Message

Mar 13 2019

US FDA 2020 Budget Request Is Parting Gift From Commissioner Gottlieb

Mar 15 2019

Clinical Trial Reform Is A Focus For CDER's 2019 Guidance Agenda

Mar 14 2019

Policy Reversal: FDA Will No Longer Require Suffixes For Older Biologics

Mar 07 2019

Gottlieb Wants His US FDA Team To Stay Together After He Departs

Mar 07 2019

Additional Topics

United States Leadership FDA Regulation BioPharmaceutical

More from Agency Leadership

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window